Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

NCT03906331 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03906331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03906331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Lead sponsor
Eli Lilly and Company
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colon cancer, medullary thyroid cancer, non small cell lung cancer, other solid tumors with evidence of activating ret alteration, pancreatic cancer, papillary thyroid cancer